Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

ELOVL3 is an important component for early onset of lipid recruitment in brown adipose tissue.

Authors: Westerberg, Rolf  MÃ¥nsson, Jan-Erik  Golozoubova, Valeria  Shabalina, Irina G  Backlund, Emma C  Tvrdik, Petr  Retterstøl, Kjetil  Capecchi, Mario R  Jacobsson, Anders 
Citation: Westerberg R, etal., J Biol Chem. 2006 Feb 24;281(8):4958-68. doi: 10.1074/jbc.M511588200. Epub 2005 Dec 2.
Pubmed: (View Article at PubMed) PMID:16326704
DOI: Full-text: DOI:10.1074/jbc.M511588200

During the recruitment process of brown adipose tissue, the mRNA level of the fatty acyl chain elongase Elovl3 is elevated more than 200-fold in cold-stressed mice. We have obtained Elovl3-ablated mice and report here that, although cold-acclimated Elovl3-ablated mice experienced an increased heat loss due to impaired skin barrier, they were unable to hyperrecruit their brown adipose tissue. Instead, they used muscle shivering in order to maintain body temperature. Lack of Elovl3 resulted in a transient decrease in the capacity to elongate saturated fatty acyl-CoAs into very long chain fatty acids, concomitantly with the occurrence of reduced levels of arachidic acid (C20:0) and behenic acid (C22:0) in brown adipose tissue during the initial cold stress. This effect on very long chain fatty acid synthesis could be illustrated as a decrease in the condensation activity of the elongation enzyme. In addition, warm-acclimated Elovl3-ablated mice showed diminished ability to accumulate fat and reduced metabolic capacity within the brown fat cells. This points to ELOVL3 as an important regulator of endogenous synthesis of saturated very long chain fatty acids and triglyceride formation in brown adipose tissue during the early phase of the tissue recruitment.


Gene Ontology Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 13673782
Created: 2018-06-23
Species: All species
Last Modified: 2018-06-23
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.